Navigation Links
AFFiRiS AG: Vaccination Against Hypertension is Development Project No. 4 and has Already Been Awarded an FFG Grant of up to EUR 1.2 Million
Date:2/25/2010

tly which often doesn't work out. Our vaccine is intended to lower the burden of strictly following this medication dictate, thereby contributing to ensuring lasting success. Taking into account the long term aspect of how hypertension leads to the often fatal sequelae such as heart diseases, stroke and kidney problems in the long term, sustainability is key for treatment's success".

The idea of intervening in the body hormone regulation of blood pressure by means of a vaccine arose in recent years. Dr Schmidt explains: "In order to develop a vaccine that can reduce hypertension, it must be able to trigger a highly specific immune response. The blood pressuring- increasing angiotensin II and the blood pressure-reducing angiotensin 1-7 differ by only one amino acid, while the remainder of the structure is identical. Our AFFITOME(R) technology allows us to adjust the immune response such that only angiotensin II is addressed. There was a similarly tricky problem in our first project, the Alzheimer's vaccine which we also solved successfully."

About AFFiRiS AG (date February 2010):

On the basis of the company's own patents, AFFiRiS develops tailor-made peptide vaccines against Alzheimer's disease, atherosclerosis, Parkinson's disease and four other conditions with an urgent medical requirement and att
'/>"/>

SOURCE AFFiRiS AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
2. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
3. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
4. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
5. AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimers Vaccine Candidate AD02 into Clinical Phase II Testing
6. Persistent Vaccination Effect of GRAZAX(R) After Completion of Treatment
7. New study indicates smallpox vaccination effective for decades
8. New study indicates smallpox vaccination effective for decades
9. Insect cells provide the key to alternative swine flu vaccination
10. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
11. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015   PureTech , a science and ... disruptive products and technologies in the healthcare sector, announced ... CEO and Member of the Board of Directors of ... "It,s has been a pleasure to know Chris for ... will be working together more closely now," said Dr. ...
(Date:2/26/2015)... , Feb. 26, 2015  23andMe, the leading ... Kate Black as Privacy Officer and Corporate Counsel. ... state privacy laws as well as health care regulations. ... she will be responsible for reviewing, updating and enhancing ... the U.S. and abroad. She joined the company January ...
(Date:2/26/2015)... JOLLA, Calif. , Feb. 26, 2015   ... a biopharmaceutical company leading the discovery and development of ... G. Xanthopoulos , Ph.D., President and Chief Executive Officer ... Cowen and Company 35 th Annual Healthcare Conference ... The conference is being held at the Boston Marriott ...
(Date:2/26/2015)... The Movement for Indefinite Life Extension ... extension technologies and awareness. The event is taking place ... March 21st 2015, in a live Google Hangout broadcast ... Founder of MILE, says, “Our lives are in our ... for Indefinite Life Extension is raising awareness about bio-sciences ...
Breaking Biology Technology:Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 423andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3
... BNVI ) today announced results for the second ... did not report any revenue for the three and ... $7,500 for the three and six,months ended June 30, ... with a Taiwanese company. In October of 2007,we terminated ...
... insulin and Apo AI(Milano), milestones, TSX ... SemBioSys Genetics Inc.,(TSX:SBS), a biotechnology company developing a ... today announced its,2008 second quarter financial and operational ... - Submitted an Investigational New Drug ...
... Transgenomic Inc. (OTC,Bulletin Board: TBIO.OB) announces the following Webcast:, What: ... Conference Call, When: ... Where: http://www.transgenomic.com/events.asp?id=6 , How: ... the address ...
Cached Biology Technology:Bionovo Reports Second Quarter 2008 Financial Results 2Bionovo Reports Second Quarter 2008 Financial Results 3Bionovo Reports Second Quarter 2008 Financial Results 4Bionovo Reports Second Quarter 2008 Financial Results 5Bionovo Reports Second Quarter 2008 Financial Results 6Bionovo Reports Second Quarter 2008 Financial Results 7SemBioSys announces second quarter 2008 financial and operational results 2SemBioSys announces second quarter 2008 financial and operational results 3SemBioSys announces second quarter 2008 financial and operational results 4SemBioSys announces second quarter 2008 financial and operational results 5SemBioSys announces second quarter 2008 financial and operational results 6SemBioSys announces second quarter 2008 financial and operational results 7SemBioSys announces second quarter 2008 financial and operational results 8SemBioSys announces second quarter 2008 financial and operational results 9SemBioSys announces second quarter 2008 financial and operational results 10SemBioSys announces second quarter 2008 financial and operational results 11SemBioSys announces second quarter 2008 financial and operational results 12SemBioSys announces second quarter 2008 financial and operational results 13
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
(Date:2/5/2015)... 26, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... http://www.nxt-id.com/ ) as part of its 2015 marketing and ... launched its new consumer website for Wocketwallet.com earlier this ... of NXT-ID said, "Our new corporate website naturally showcases ...
(Date:2/5/2015)... January 28, 2015 New Market ... And Segment Forecasts To 2020 has Been Added to ... market is expected to reach USD 5.10 billion by ... Research, Inc. IR cameras help identify the site of ... to witness surging demand in medical imaging applications. They ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... origami", the way that proteins fold is vital to ... of Leeds have discovered this is a ,hit and ... before they form the correct structure for their intended ... functions and play a crucial role in the growth, ...
... of a previously unknown protein in the cells of ... diagnosis of a serious lung disease. The findings, ... journal Proceedings of the National Academy of Sciences ... of common diseases like asthma and chronic bronchitis. ...
... levels of vitamin B12 shortly before and after conception may ... to an analysis by researchers at the National Institutes of ... Ireland. Women with the lowest B12 levels had 5 ... tube defect compared to women with the highest B12 levels. ...
Cached Biology News:Unfolding 'nature's origami' 2Low levels of vitamin B12 may increase risk for neural tube defects 2Low levels of vitamin B12 may increase risk for neural tube defects 3Low levels of vitamin B12 may increase risk for neural tube defects 4
... for a single fragment based screening project: , ... 96 shape-diverse mixtures of 4 (5 uL ... for structure refinement , Individual compounds are ... at ca. 50 mM. Supplied in 5 96-well trays. ...
... (PR) Competitor Assay Kits are ideal ... receptor binding compounds using fluorescence polarization ... fusion of glutathione transferase to the ... receptor [PR-LBD(GST)] and a proprietary, fluorescently-tagged ...
... CHEMICONs Alkaline Phosphatase Detection Kit (Catalog ... tool for the phenotypic assessment of ES ... activity. Available separately from CHEMICON are ... and TRA-2-54 (Catalog Number MAB4354), which permit ...
... A and Protein G bind specifically to ... A and Protein G conjugates are commonly ... (antibodies) and immunoglobulin subtypes from serum, hybridoma ... biological fluids. These reagents are also commonly ...
Biology Products: